AbbVie stock holds after Q2 2026 earnings beat and updated guidance
Published on 08/28/2026 at 19:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie Inc. (US00287Y1091) stock continues to trade close to its recent highs as investors digest a Q2 2026 earnings beat and refreshed guidance reported on July 31, 2026. As of August 27, 2026, AbbVie shares changed hands near $258 in New York, reflecting a valuation in the mid-hundreds of billions of dollars and leaving room against the current analyst consensus target.
Q2 2026 earnings beat with double-digit growth
In its earnings release for the quarter ended June 30, 2026, AbbVie reported net revenue of $16.99 billion, up 10.2 percent compared with the same period in 2025, highlighting continued momentum across its immunology and hematologic oncology franchises. The company also delivered adjusted diluted earnings per share of $3.65 for Q2 2026, an increase of 22.9 percent year over year from $2.97, and modestly above the consensus estimate of $3.61.
Profitability metrics showed a solid profile for the quarter ended June 30, 2026. AbbVie reported a GAAP operating margin of 37.9 percent and an adjusted operating margin of 48.3 percent, while GAAP gross margin reached 74.7 percent and adjusted gross margin came in at 84.7 percent. Selling, general and administrative expenses represented 21.4 percent of sales on a GAAP basis in Q2 2026, with an adjusted ratio of 21.0 percent, and research and development spending accounted for 13.8 percent of revenue, or 13.6 percent on an adjusted basis in the same quarter.
On a reported basis for the quarter ended June 30, 2026, diluted GAAP earnings per share reached $2.03, reflecting a year-over-year increase of 290.4 percent, helped by lower one-time charges and a favorable comparison to prior-year restructuring and amortization effects. The combination of double-digit revenue growth and expanding profit metrics reinforces AbbVie’s capacity to fund its dividend, invest in its pipeline and manage the continuing erosion of legacy products such as Humira.
Guidance, dividend and analyst consensus
Alongside the Q2 2026 report, AbbVie updated its full-year 2026 adjusted diluted EPS guidance to a range of $13.87 to $14.07, modestly trimming the prior range of $13.91 to $14.11 once the impact of recent acquisitions was factored in. For the next quarter, management set Q3 2026 adjusted EPS guidance between $3.84 and $3.88, pointing to another sequentially strong period and a continuation of double-digit earnings growth versus the prior-year quarter.
For income-oriented investors, AbbVie maintained its cash return profile. The company’s most recent quarterly dividend of $1.73 per share was paid on August 14, 2026 to shareholders of record as of July 15, 2026, indicating an annualized dividend of $6.92 per share and a yield of about 2.7 percent at stock prices near the high-$250s. This dividend track record, tied to current earnings power that is guided to the high teens per share, underpins AbbVie’s positioning as a large-cap biopharmaceutical income name.
Market data compiled by equity research aggregators show that AbbVie carries an average rating in the moderate buy zone and an average price target of $276.59 per share, based on 31 individual analyst opinions as of August 28, 2026. With the last closing price reported at $258.15 on the New York Stock Exchange, the consensus target implies roughly 7.1 percent upside and a high-end target of $328.00 suggests a potential gain of more than 27 percent from recent levels, while the lowest published target of $200.00 sits more than 22 percent below the latest close.
Ownership flows and market valuation context
Recent filings highlight active institutional positioning in AbbVie stock in August 2026. Several investment managers disclosed increased stakes, while others reported partial profit-taking, reflecting normal portfolio rebalancing in a large-cap healthcare name that has appreciated more than 12 percent since the start of 2026 at recent prices. One institutional update noted an opening price of $258.23 for AbbVie on the latest trading session referenced, broadly consistent with other real-time quotes indicating the shares trading in the mid-$250s.
At current levels, AbbVie’s market capitalization stands in the mid-$450 billion area as referenced by large-capitalization tracking services as of late August 2026, placing the company among the most valuable global pharmaceutical and biotechnology groups. This valuation is anchored by its portfolio of immunology blockbusters such as Skyrizi and Rinvoq, selective oncology assets, and a pipeline designed to offset the continuing decline of legacy revenues from products like Humira, which have faced biosimilar competition.
From a performance standpoint, quote overviews indicate that AbbVie stock is up almost 13 percent year to date as of August 28, 2026, outpacing broader healthcare benchmarks and reflecting investor confidence in the company’s execution on post-Humira strategy. Five-day percentage change figures have recently been slightly negative, underscoring a modest consolidation phase after strong gains; however, the year-to-date trend remains positive, and the shares continue to trade in the upper portion of their 52-week price range.
Immunology and key products drive the story
The investment narrative for AbbVie in 2026 centers on its immunology franchise, particularly the growth trajectories of Skyrizi and Rinvoq, which are designed to replace and surpass historical revenue contributions from Humira in indications such as psoriasis, psoriatic arthritis and rheumatoid arthritis. In the latest quarter ended June 30, 2026, the double-digit revenue increase suggests that newer therapies are more than offsetting declines in more mature products, reflecting strong uptake and expanding labels.
Beyond immunology, AbbVie continues to generate meaningful revenue from its hematologic oncology portfolio, neurology treatments and aesthetic medicine business. These segments help diversify cash flows and provide additional levers for earnings growth. Management commentary around Q2 2026 highlighted that the company’s margin structure benefits from the high gross margins associated with biologic drugs and specialty therapies, which support reinvestment into clinical development and business development transactions.
Looking forward, AbbVie’s updated full-year guidance and Q3 2026 EPS range suggest management is balancing organic growth with integration of recent acquisitions identified in the Q2 2026 disclosures. The slightly lower adjusted EPS range for the full year reflects integration costs and investment spending, but still points to a robust earnings baseline in the mid-teens per share, which compares favorably against the annualized dividend of $6.92 and leaves significant room for pipeline investment and balance-sheet management.
Representative product spotlight
One representative product that illustrates AbbVie’s post-Humira transition is Skyrizi, a monoclonal antibody targeting the IL-23 pathway that has become a leading therapy for plaque psoriasis and is expanding into additional indications. Skyrizi’s growth in recent quarters has been a key contributor to the company’s double-digit revenue increase reported for Q2 2026, demonstrating how next-generation immunology assets are taking over the role of primary growth drivers within AbbVie’s portfolio.
Stock price context and investor takeaway
As of August 27, 2026, AbbVie stock was quoted at $258.42 on the New York Stock Exchange, following a 1.7 percent decline in late trading from a prior close of $262.90, according to market data snapshots of that session. Intraday trading on the preceding day saw the shares fluctuate between approximately $257.25 and the low-$260s, underlining that the current price level is still comfortably above the lows of the past year and close to the latest closing print of $258.15 used in consensus calculations.
Company profile and market data
Company: AbbVie Inc.
ISIN: US00287Y1091
Ticker: ABBV
Exchange: New York Stock Exchange (primary listing)
Price (as of August 27, 2026, 8:26 p.m. ET): $258.42 USD
Market cap: $456.18 billion (as of August 28, 2026)
Sector / Industry: Health Care / Pharmaceuticals and Biotechnology
Index membership: S&P 500
